Key result
Chemotherapy treatment was associated with prolonged median survival (18 vs. 1 month; HR 0.16; 95% CI 0.47-0.54; P=0.0003) in patients with cardiac non-Hodgkin's lymphoma.
Why the study?
Does chemotherapy treatment improve survival in patients with cardiac non-Hodgkin's lymphoma?
Population
94 cases of non-Hodgkin's lymphoma with biopsy-proven cardiac involvement reported in PubMed between 1990…
Comparison
Chemotherapy treatment vs No chemotherapy treatment
Design
Systematic_review
Follow-up
up to 72 months (median survival 3 months)
Authors
Loading...
Observed survival benefit with chemotherapy in cardiac NHL should not yet change practice; hypothesis-generating association requires prospective confirmation.
Observational (n=94)
Does chemotherapy treatment improve survival in patients with cardiac non-Hodgkin's lymphoma?
Hazard Ratio: 0.16 (95% CI 0.47–0.54)
Absolute Event Rate: 18% vs 1%
p-value: p=0.0003
Chemotherapy significantly prolongs survival in patients with cardiac non-Hodgkin's lymphoma, who otherwise have a very poor prognosis.
Gordon et al. (2016) conducted an observational in Cardiac non-Hodgkin's lymphoma (NHL) (n=94). Chemotherapy treatment vs. No chemotherapy was evaluated on Median survival (HR 0.16, 95% CI 0.47-0.54, p=0.0003). Chemotherapy treatment was associated with prolonged median survival (18 vs. 1 month; HR 0.16; 95% CI 0.47-0.54; P=0.0003) in patients with cardiac non-Hodgkin's lymphoma.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: